Biopharmaceutical Company Announces Enters Into Major Financial Transaction With Life Sciences Giant

Esperion, a well-known entity in the biopharmaceutical industry trading under the Nasdaq symbol ESPR, has recently entered into a pivotal financial transaction with OMERS Life Sciences, a prominent investor in the life sciences sector. The essence of this transaction revolves around a Royalty Purchase Agreement (the Agreement) through which Esperion has sold its future royalty entitlements from the sales of bempedoic acid products in Europe. Bempedoic acid, a key pharmaceutical product for which Daiichi Sankyo Europe (DSE) holds exclusive licensing rights in Europe from Esperion, plays a central role in this agreement. $Esperion Therapeutics(ESPR.US)$